ArticleScientific reports2026
COPD prescription patterns after the 2018 Japan floods: analysis of national data.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Climate change has led to an increase in flood disasters worldwide, raising concerns about their potential impact on respiratory health. This study investigated the impact of the 2018 Japan Floods, one of the largest flood disasters in Japan's history, on prescription rates for chronic obstructive pulmonary disease (COPD). To examine the impact of the disaster on COPD-related prescriptions, we analysed anonymised health insurance claims data from the Japanese National Database. The study focused on residents of three prefectures that included the most severely affected areas during the 2018 Japan Floods, covering a 2-year observation period-1 year before and 1 year after the disaster. First, we compared new prescriptions of long-acting inhaled COPD medications after the disaster between victims and non-victims among individuals who had not received such prescriptions during the previous year (n = 3,674,535). Second, we examined prescriptions for antibiotics or systemic steroids after the disaster among individuals already receiving long-acting inhaled COPD medications before the disaster (n = 18,059), as indicators of COPD exacerbations. Cox proportional hazards models showed that new prescriptions for long-acting inhaled COPD medications were significantly higher among disaster victims than among non-victims in the year following the 2018 Japan Floods (aHR: 1.56; 95% CI [1.25-1.95]). Difference-in-differences analysis showed that exacerbation-related prescriptions significantly increased among disaster victims compared with non-victims (aROR: 1.50; 95% CI [1.06-2.11]). New prescriptions for COPD controller medications and exacerbation-related prescriptions significantly increased in populations affected by the 2018 Japan Floods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.